ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
Sign Up to like & getrecommendations! Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.157081
Abstract: The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment. In this study, we demonstrated the role of interferon-stimulated 20… read more here.
Keywords: bortezomib; psmb5; activity; isg20l2 ... See more keywords